Epidemiological typing of nosocomial carbapenem-resistant Acinetobacter baumannii isolates by molecular genetic methods and whole-genome sequencing-based techniques

Authors

  • T. Strateva Department of Medical Microbiology “Corr. Mem. Prof. Ivan Mitov, MD, DMSc”, Faculty of Medicine, Medical University – Sofia Author https://orcid.org/0000-0002-5197-1849
  • A. Stratev Clinic of Anaesthesiology and Intensive Care, UMHAT “Sv. Ivan Rilski” – Sofia; Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Medical University – Sofia Author https://orcid.org/0009-0001-3856-4536
  • S. Dimov Department of Genetics, Faculty of Biology, Sofia University “Sv. Kliment Ohridski” Author https://orcid.org/0000-0002-2564-2427
  • A. Kolevski Central Laboratory of Microbiology, UMHAT “Alexandrovska” – Sofia Author
  • S. Peykov Department of Medical Microbiology “Corr. Mem. Prof. Ivan Mitov, MD, DMSc”, Faculty of Medicine, Medical University – Sofia; Department of Genetics, Faculty of Biology, Sofia University “Sv. Kliment Ohridski”; BioInfoTech Laboratory, Sofia Tech Park – Sofia Author https://orcid.org/0000-0001-9431-9511

Keywords:

carbapenem-resistant Acinetobacter baumannii isolates, multiplex PCR to identify sequence groups and clones, whole-genome sequencing, multilocus sequence typing, KL typing, OCL typing, international clone 2, global high-risk clone ST2

Abstract

The present study aimed to perform epidemiological typing of nosocomial carbapenem-resistant Acinetobacter baumannii (CRAB) isolates from four university hospitals in Bulgaria using molecular genetic methods and whole-genome sequencing (WGS)-based techniques. A total of 80 CRAB (2014-2024) preliminary identified by automated systems were investigated. Methodology included antimicrobial susceptibility testing, polymerase chain reaction (PCR) to detect carbapenemase-encoding genes, WGS, multiplex PCR to identify sequence groups and international clones (ICs), multilocus sequence typing (MLST), KL (capsular polysaccharide locus), and OCL (outer core lipooligosaccharide locus) typing. CRAB studied were categorized as isolates with multidrug (8.8%), extensive drug (52.5%), and extensive drug + difficult-to-treat antimicrobial resistance (38.8%). Acquired class D carbapenemases were identified with the following prevalence rates: 92.5% OXA-23-like, 3.8% OXA-24/40-like, and 3.8% OXA-23-like + OXA-24/40-like. WGS proved OXA-23 and OXA-72 (OXA-24/40-like group). Multiplex PCR results showed a predominance of IC2 (76.7%), followed by sequence group G5 (15%). In WGS-based MLST analysis of 20 CRAB isolates, nineteen belonged to sequence type (ST) 2 (IC2) and one to ST636 (IC2). ST2 was associated with OCL1 and several KL types (KL9, KL77, KL2, and KL3), while ST636, with OCL2 and KL40, respectively. In conclusion, the conducted epidemiological typing of CRAB isolates revealed a clear dominance of IC2 (82.5% overall, as determined by both groups of methods) and the global high-risk ST2 clone (95%) in the monitored hospitals over the 10-year follow-up period. KL typing is a valuable tool with high discriminatory power to distinguish nosocomial A. baumannii isolates by chronology and site of isolation.

References

Sharma R, Lakhanpal D. Acinetobacter baumannii: A comprehensive review of global epidemiology, clinical implications, host interactions, mechanisms of antimicrobial resistance and mitigation strategies. Microb Pathog, 2025, 204: 107605.

Alenazi TA, Shaman MSB, Suliman DM, et al. The impact of multidrug-resistant Acinetobacter baumannii infection in critically ill patients with or without COVID-19 infection. Healthcare (Basel), 2023, 11 (4): 487.

Gedefie A, Demsis W, Ashagrie M, et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: A review. Infect Drug Resist, 2021, 14: 3711-3719.

Thacharodi A, Vithlani A, Hassan S, et al. Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens. iScience, 2024, 27 (12): 111367.

CDC. Antibiotic resistance threats in the United States, 2021-2022. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2024. Available online: https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html [Accessed 31 January 2026].

World Health Organization. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024. Available online: https://www.who.int/publications/i/item/9789240093461 [Accessed 31 January 2026].

Pogue JM, Zhou Y, Kanakamedala H, Cai B. Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infect Dis, 2022, 22 (1): 36.

Zhen X, Chen Y, Hu X, et al. The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China. Eur J Clin Microbiol Infect Dis, 2017, 36 (10): 1989-1994.

Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022, 399 (10325): 629-655.

Papathanakos G, Andrianopoulos I, Papathanasiou A, et al. Pandrug-resistant Acinetobacter baumannii treatment: still a debatable topic with no definite solutions. J Antimicrob Chemother, 2020, 75 (10): 3081.

Boutzoukas A, Doi Y. The global epidemiology of carbapenem-resistant Acinetobacter baumannii. JAC Antimicrob Resist, 2025, 7 (4): dlaf134.

Shelenkov A, Akimkin V, Mikhaylova Y. International clones of high risk of Acinetobacter baumannii – definitions, history, properties and perspectives. Microorganisms, 2023, 11 (8): 2115.

Hansen F, Porsbo LJ, Frandsen TH, et al. Characterisation of carbapenemase-producing Acinetobacter baumannii isolates from Danish patients 2014-2021: detection of a new international clone – IC11. Int J Antimicrob Agents, 2023, 62 (2): 106866.

Xu A, Li M, Hang Y, et al. Multicenter retrospective genomic characterization of carbapenemase-producing Acinetobacter baumannii isolates from Jiangxi patients 2021-2022: identification of a novel international clone, IC11. mSphere, 2024, 9 (6): e0027624.

Anwer R. Molecular epidemiology and molecular typing methods of Acinetobacter baumannii: An updated review. Saudi Med J, 2024, 45 (5): 458-467.

Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, 2012, 18 (3): 268-281.

Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis, 2018, 67 (12): 1803-1814.

Strateva TV, Sirakov I, Stoeva TJ, et al. Phenotypic and molecular characteristics of carbapenem-resistant Acinetobacter baumannii isolates from Bulgarian intensive care unit patients. Microorganisms, 2023, 11 (4): 875.

Turton JF, Gabriel SN, Valderrey C, et al. Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii. Clin Microbiol Infect, 2007, 13 (8): 807-815.

Karah N, Sundsfjord A, Towner K, Samuelsen Ø. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist Updat, 2012, 15 (4): 237-247.

Wyres KL, Cahill SM, Holt KE, et al. Identification of Acinetobacter baumannii loci for capsular polysaccharide (KL) and lipooligosaccharide outer core (OCL) synthesis in genome assemblies using curated reference databases compatible with Kaptive. Microb Genom, 2020, 6 (3): e000339.

Cahill SM, Hall RM, Kenyon JJ. An update to the database for Acinetobacter baumannii capsular polysaccharide locus typing extends the extensive and diverse repertoire of genes found at and outside the K locus. Microb Genom, 2022, 8 (10): mgen000878.

Pearl S, Anbarasu A. Genomic landscape of nosocomial Acinetobacter baumannii: A comprehensive analysis of the resistome, virulome, and mobilome. Sci Rep, 2025, 15 (1): 18203.

Li S, Jiang G, Wang S, et al. Emergence and global spread of a dominant multidrug-resistant clade within Acinetobacter baumannii. Nat Commun, 2025, 16 (1): 2787.

Borges Duarte DF, Gonçalves Rodrigues A. Acinetobacter baumannii: insights towards a comprehensive approach for the prevention of outbreaks in health-care facilities. APMIS, 2022, 130 (6): 330-337.

Rahman A, Styczynski A, Khaleque A, et al. Genomic landscape of prominent XDR Acinetobacter clonal complexes from Dhaka, Bangladesh. BMC Genomics, 2022, 23 (1): 802.

Thoma R, Seneghini M, Seiffert SN, et al. The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature. Antimicrob Resist Infect Control, 2022, 11 (1): 12.

Castanheira M, Mendes RE, Gales AC. Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex. Clin Infect Dis, 2023, 76 (Suppl 2): S166-S178.

Towner KJ, Levi K, Vlassiadi M, ARPAC Steering Group. Genetic diversity of carbapenem-resistant isolates of Acinetobacter baumannii in Europe. Clin Microbiol Infect, 2008, 14 (2): 161-167.

Karah N, Giske CG, Sundsfjord A, Samuelsen Ø. A diversity of OXA-carbapenemases and class 1 integrons among carbapenem-resistant Acinetobacter baumannii clinical isolates from Sweden belonging to different international clonal lineages. Microb Drug Resist, 2011, 17 (4): 545-549.

Hummel D, Juhasz J, Kamotsay K, et al. Genomic investigation and comparative analysis of European high-risk clone of Acinetobacter baumannii ST2. Microorganisms, 2024, 12 (12): 2474.

Kostyanev T, Xavier BB, García-Castillo M, et al. Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study. Int J Antimicrob Agents, 2021, 57 (6): 106345.

Frenk S, Temkin E, Lurie-Weinberger MN, et al. Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. J Antimicrob Chemother, 2022, 77 (4): 934-943.

Valcek A, Nesporova K, Whiteway C, et al. Genomic analysis of a strain collection containing multidrug, extensively drug-, pandrug-, and carbapenem-resistant modern clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother, 2022, 66 (9): e0089222.

Gajic I, Jovicevic M, Milic M, et al. Clinical and molecular characteristics of OXA-72-producing Acinetobacter baumannii ST636 outbreak at a neonatal intensive care unit in Serbia. J Hosp Infect, 2021, 112: 54-60.

Dobrović K, Škrobo T, Selec K, et al. Healthcare-associated bloodstream infections due to multidrug-resistant Acinetobacter baumannii in COVID-19 intensive care unit: A single-center retrospective study. Microorganisms, 2023, 11 (3): 774.

Tafaj S, Kostyanev T, Xavier BB, et al. Clonal transmission of multidrug-resistant Acinetobacter baumannii harbouring blaOXA-24-like and blaOXA-23-like genes in a tertiary hospital in Albania. J Glob Antimicrob Resist, 2020, 23: 79-81.

Maure A, Robino E, Van der Henst C. The intracellular life of Acinetobacter baumannii.

Published

20.04.2026

Issue

Section

Original articles

How to Cite

Strateva, T., Stratev, A., Dimov, S., Kolevski, A., & Peykov, S. (2026). Epidemiological typing of nosocomial carbapenem-resistant Acinetobacter baumannii isolates by molecular genetic methods and whole-genome sequencing-based techniques. Medical Review, 62(3), 19-30. https://journals.mu-sofia.bg/index.php/mr/article/view/766